Curis

curis is a publicly-traded biotechnology company (nasdaq: cris) focused on the development of first-in-class and innovative therapeutics or the treatment of cancer. the company currently has three drug candidates in development: - emavusertib (ca-4948), an orally-available, small molecule inhibitor of the irak4 kinase being investigated in a phase 1 clinical trial in patients with non-hodgkin's lymphoma and in a separate phase 1 trial for acute myeloid leukemia and myelodysplastic syndromes. - ci-8993, a monoclonal antibody designed to antagonize the v-domain ig suppressor of t cell activation, or vista signaling pathway, being investigated in a phase 1a/1b trial in patients with solid tumors. - fimepinostat, an orally available, small molecule inhibitor of hdac and pi3k enzymes, which is currently being evaluated for future studies. curis is engaged in a collaboration with aurigene for discovery and development of drug candidates in the area of immuno-oncology and precision oncology. as part of this collaboration, curis has exclusive licenses to oral small molecule dual antagonists of pd1 and vista, including pdl1/vista antagonist ca-170, and oral small molecule dual antagonists of pd1 and tim3, including pdl1/tim3 antagonist ca-327, as well as to molecules designed to inhibit the irak4 kinase, including ca-4948. the company's collaborators, f. hoffmann-la roche ltd, or roche, and genentech inc., or genentech, a member of the roche group, are commercializing erivedge®(vismodegib) for the treatment of patients with advanced basal cell carcinoma, or bcc. we are seeking dedicated, driven, humble, hands-on professionals, from diverse backgrounds, who are passionate about making a difference in the lives of patients and families touched by cancer, and who want to have some fun while doing it. for more information, visit curis's website at www.curis.com.